We designed the EURAMOS-1 trial to investigate whether intensified .. and a normal creatinine concentration for their age as per protocol. EURAMOS-1, an international randomised study for osteosarcoma: Results from Pre-operative chemotherapy was completed according to protocol in 94%. The EURAMOS 1 trial is a multimodal therapy of osteosacoma with precluding treatment with protocol chemotherapy (for example HIV.

Author: Mazucage Tozshura
Country: Suriname
Language: English (Spanish)
Genre: Life
Published (Last): 17 March 2014
Pages: 289
PDF File Size: 3.31 Mb
ePub File Size: 20.97 Mb
ISBN: 393-6-94382-214-1
Downloads: 25226
Price: Free* [*Free Regsitration Required]
Uploader: Majar

New models of collaboration are required to successfully conduct trials to improve outcomes of patients with rare cancers; EURAMOS-1 demonstrates achievability. The role of interferons in the treatment of osteosarcoma. Of those patients, one Good Responder had worst toxicity of grade 1; one poor responder had worst toxicity of grade 3 and one person with unknown histological response had a worst toxicity of grade 4.

A randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy.

Page Not Found

Response assessment was required to determine suitability for surgery and to exclude progression see supplementary Material, available at Annals of Oncology online. Acknowledgement of research support: York Find articles by P.

University Hospital Ghent, Gent, Belgium. Planning the size and duration of a clinical trial studying the time to some critical event. Osteosarcoma is the commonest primary bone cancer affecting young people with an overall age-standardised incidence rate of 5.


Secondary outcome measures were overall survival OStoxicity and QL. In the latter case, please turn on Javascript support in your web browser and reload this page. Gene Ontology GO Terms.

Toxicities were consistent with previous experience of these agents. This paper describes the full, registered patient population, including all patients who signed the informed consent documents, up to the point of surgery.

Quality of life in children and adolescents with cancer. Goorin18 R. Recruitment was completed to the largest osteosarcoma study to date in 75 months.

It assessed maintenance therapy in patients with a better prognosis Good Response [ 19 ] and intensification in patients with poorer prognosis Poor Response [ 920 — 22 ]. There were limits to the accessibility of the trial for osteosarcoma patients. Morris30, 31 H.

Nadel33 R. Improvement in the following outcomes Overall survival Short-term toxicity Long-term toxicity Quality of life. Considerable regulatory, financial and operational challenges must be overcome to develop similar studies in the future. Methotrexate was given over 4 h and folinic acid rescue commenced at 24 h. The study was developed through a commitment to collaboration between four well-established study groups.

Or filter your current search. Commencing Marchpatients were protoco, from centres across 17 countries. Median time from start of chemotherapy to surgery was 82 days IQR 76; Main objectives To examine in a randomized trial, whether the addition prootocol ifosfamide and etoposide IE to post-operative chemotherapy with cisplatin, doxorubicin and methotrexate improves event-free survival for patients with resectable osteosarcoma and a poor histological response to 10 weeks of pre-operative chemotherapy.


Once histological response to pre-operative chemotherapy has been evaluated, patients will be randomized by contacting the relevant trials center. J Natl Cancer Inst. There were three 0.

Page Not Found | MRC Clinical Trials Unit at UCL

Lau27 G. National Center for Biotechnology InformationU. Long-term event data were sought in all patients, regardless of randomisation.

Bielack2 N. Baseline characteristics at registration.

How does Europe PMC derive its citations network? Calaminus11 M. Gorlick eufamos, 19 G. Meyers30 C. Jundt24 L. CitePeer Related Articles http: Therefore, this study addressed separate treatment questions based on histological response. Butterfass-Bahloul9 T. It is permissible to administer up to two additional Eurmos courses and have the patient remain eligible for randomization.

A third pre-operative course of AP should not be given as this renders the patient ineligible for randomization.

Ifosfamide and etoposide in childhood osteosarcoma.